SPECIAL REPORT: The Pandemic Paradigm: Balancing Commercial Opportunities with Public Health Concerns in the Face of A/H1N1 2009

Published by	Decision Resources, Inc.
Published	October, 2009	Product code	102136
Content info	36 Pages
Price	US $ 9200 PDF by E-mail (Global License)

Introduction
Related Reports

SPECIAL REPORT: The Pandemic Paradigm: Balancing Commercial Opportunities with Public Health Concerns in the Face of A/H1N1 2009 published by Decision Resources, Inc. in October, 2009. This report consists of 36 Pages and the price starts from US $ 9200.

Introduction

Abstract

Introduction

WHO and the European Centre for Disease Prevention and Control (ECDC) are advising countries to prepare for a more severe second wave of A/H1N1 2009 in the winter of 2009-2010. This advisement could be warranted, given that no infectious disease has killed more people in a short period of time than infl uenza. Without preventive measures - such as vaccines - the current A/H1N1 ("swine fl u") 2009 pandemic could claim more than 1 million lives in the seven major markets we cover. The onus on public health agencies and the pharmaceutical industry, therefore - both now and in the future - is to learn from their past successes and failures to ensure that systems are in place that can quickly identify, prevent, and treat a pandemic virus.

Questions Answered in This Report

Prior to A/H1N1, SARS and H5N1 ("avian fl u") infl uenza were the fi rst major infectious " disease scares of the millennium. What lessons did these two events provide? How are lessons learned from these infectious outbreaks being applied to the current A/H1N1 2009 situation?
Without preventive measures such as vaccines, A/H1N1 2009 will affect a considerable number of people in the major markets under study. How many cases, hospitalizations, and deaths will result if no preventive measures are put in place?
Traditional methods of vaccine production are being challenged by new technologies. What are the old technologies and what advantages will the new vaccine technologies have over them? What companies are involved in these new technologies? How are the emerging vaccines differentiating themselves from one another?
Vaccines for A/H1N1 2009 were approved by the FDA beginning on September 15, 2009. Which companies obtained FDA approval for their vaccines? Which patient populations are each of these companies permitted to vaccinate? Despite these approvals, what obstacles stand in the way of vaccines coming out in the coming months?
Antivirals and diagnostics are useful tools in the A/H1N1 2009 fight, but each technology has room for improvement. What are the downsides to antiviral treatments? How can diagnostics be improved to assist in current or future pandemics? In which situations will certain antivirals be used, and what factors might limit the uptake of antiviral use during this pandemic?

Scope

Primary research: interviews with three infl uenza experts.
Up-to-date Decision Resources epidemiology review of A/H1N1 2009: pandemic versus seasonal infl uenza, genetic drift versus genetic shift, emerging infl uenza threats, the current pandemic (cases, hospitalizations, deaths) compared with seasonal fl u (cases, hospitalizations, deaths).
Case studies: history of infl uenza, severe acute respiratory syndrome (SARS), H5N1 infl uenza ("avian fl u" or "bird fl u").
Infl uenza vaccines: development and production processes, current egg-based technologies, current and emerging cell-based technologies, companies with approved or potential A/H1N1 2009 vaccines.
Antivirals: Tamifl u, Relenza, peramivir.
Diagnostics: recent FDA A/H1N1 2009 diagnostic approvals, challenges with infl uenza diagnostics, opportunities and needs for pandemic diagnostics.

Companies Mentioned in This Report

Abbott Laboratories
AstraZeneca
Baxter International
Becton Dickinson
BioCryst Pharmaceuticals
CSL
Dynavax Technologies
DynPort Vaccine Company
Focus Diagnostics
GlaxoSmithKline
Inverness Medical
Luminex
MedImmune
Mylan
Novavax
Novartis Vaccines and Diagnostics
Prodesse
Protein Sciences
Quest Diagnostics
Quidel
Roche
Schering-Plough
Solvay Biologicals
Solvay Pharmaceuticals
Sanofi-Aventis
Sanofi-Pasteur
Sinovac
Teva
VaxInnate

Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Past Infl uenza Pandemics and Recent Virus Scares: A Historical Perspective
SARS - the First Pandemic of the Millennium Tests Public Health Readiness
The Avian Flu: Health Scare Jump-Starts Pandemic Readiness
Current Situation: the A/H1N1 2009 Virus
Background: Seasonal Infl uenza
Genetic Shift and Drift: the Dynamics of the Infl uenza Virus
Emerging Infl uenza Threats
Pandemic Threat
Susceptible Populations
A/H1N1 2009 Pandemic
Cases
Hospitalizations
Deaths
Pandemic Prevention
Producing Infl uenza Vaccines: Challenges and Progress
Egg-Based Methods of Production
Current Cell-Based Methods
Baxter International
Solvay Pharmaceuticals
Novartis
Emerging Technologies
Protein Sciences
Novavax
VaxInnate
DynaVax Technologies
A/H1N1 2009 Vaccine Development Activities, by Company
GlaxoSmithKline
Sanofi-Aventis
Novartis
CSL
MedImmune
Baxter International
Solvay Pharmaceuticals
Sinovac
Antivirals
Diagnostics
Outlook: Summary of Lessons Learned and Scenarios Looking Forward
Lessons Learned
Possible A/H1N1 2009 Scenarios
The Probable Scenario
The Unlikely Scenario
What About Future Pandemics?
Appendix A: Bibliography
Appendix B: List of Interviewed Physicians

Tables

1. Number of Incident Cases, Hospitalizations, and Deaths Attributable to Seasonal Infl uenza and A/H1N1 2009 in the Major Markets, 2009/2010
2. U.S. Department of Health and Human Services Grants to Companies for the Development of Cell-Based Infl uenza Vaccines